(Q36294910)

13 August 2017

Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? (English)

1 reference

13 August 2017

0 references

1 reference

1 reference

Gogas H

1

1 reference

13 August 2017

Lofts FJ

2

1 reference

13 August 2017

Evans TR

3

1 reference

13 August 2017

Daryanani S

4

1 reference

13 August 2017

Mansi JL

5

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 January 1998

1 reference

British Journal of Cancer

13 August 2017

1 reference

13 August 2017

77

1 reference

13 August 2017

2

1 reference

13 August 2017

325-328

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1998.50

13 August 2017

0 references

cites work

A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2151236

Phase II study of gemcitabine in patients with advanced pancreatic cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2151236

The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2151236

Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2151236

Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2151236

The clinical utility of the CA 19-9 tumor-associated antigen.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2151236

A review of the role of established tumour markers

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2151236

Radiation therapy and 5-fluorouracil modulated by leucovorin for adenocarcinoma of the pancreas

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2151236

Colorectal carcinoma antigens detected by hybridoma antibodies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2151236

The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2151236

Chemotherapy prolongs survival in inoperable pancreatic carcinoma.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2151236

CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer

22 September 2018

1 reference

12 December 2020

Determination and significance of a new carbohydrate antigen CA19-9 in digestive system cancers

1 reference

12 December 2020

CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases

1 reference

12 December 2020

Circadian rhythm modulated 5-FUdR infusion with Megace in the treatment of advanced pancreatic cancer

1 reference

12 December 2020

Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9

1 reference

12 December 2020

Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic cancer

1 reference

12 December 2020

The use of the tumour marker CA19-9 in evaluating the response to tamoxifen therapy in patients with unresectable adenocarcinoma of the pancreas

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1998.50

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

9461005

1 reference